Abstract
Glatiramer acetate (Copaxone®) is a disease-modifying agent approved by several health authorities worldwide for the treatment of relapsing-remitting multiple sclerosis. Although its primary target is the inflammatory component of the disease, there are emerging pieces of evidence suggesting that glatiramer acetate might also have a neuroprotective effect. In this review, the results of glatiramer acetate clinical trials and other relevant studies as well as the place of glatiramer acetate among other approved disease-modifying treatments for relapsing-remitting multiple sclerosis are discussed critically.
| Original language | English |
|---|---|
| Pages (from-to) | 451-458 |
| Number of pages | 8 |
| Journal | Expert Review of Neurotherapeutics |
| Volume | 5 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Jul 2005 |
Keywords
- Glatiramer acetate
- Immunomodulation
- Multiple sclerosis
ASJC Scopus subject areas
- Clinical Neurology
- Neuroscience(all)